Nanotech's rising star in drug delivery; Halozyme books beaucoup revenue;

> The executive director of the Birla Institute of Scientific Research provides a broad overview on the status and future of nanotechnology in medicine. Item

>Halozyme booked nearly $23 million in revenue for its fiscal 2011 third quarter. The company also touts a number of upcoming milestones, including the reintroduction of Hylenex recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and ambulatory surgery centers. Release

>Arrowhead Research Corporation has published a white paper detailing its proprietary dynamic polyconjugate (DPC) technology to deliver siRNA. Release

>Alkermes' Vivitrol, an extended-release injectable drug to treat alcohol or drug dependence, has generated positive results in a new long-term 18-month study. Details

> DSM will supply Svelte a bioerodible drug carrier for a drug-eluting stent system. Story